A method for preventing radiation-induced ototoxicity in an individual in need thereof comprising intratympanic administration of a pharmaceutical composition comprising a therapeutic agent selected from a JNK inhibitor, TRPV modulator, an MET channel inhibitor, and an otoprotectant to the individual in need thereof, wherein the pharmaceutical composition is administered prior to onset of radiation therapy, and wherein the composition provides sustained release of the therapeutic agent into the ear for a period of at least 5 days after a single administration
Beta-3 adrenergic receptors, the primary target of AOD-9604, are highly expressed in white and brown adipose tissue but have minimal presence in appetite-regulating brain regions
Sun conducted a survey in 48 states of the United States to study the relationship between the concentrations of Se, strontium, and magnesium in soil and the mortality rate of PD in the United States
Quantification of IL-6, IL-8, IL-1 and PGE2 by enzyme-linked immunoassay (ELISA) Supernatants obtained from the qPCR assay were centrifuged at 600 g for 6 min and used to estimate concentration using bovine IL-8 ELISA kits (#3114-1A-6, Mabtech, Nacka, Sweden), IL-6 (#ESS0029, Thermo Fisher Scientific), IL-1 (#ESS0027, Thermo Fisher Scientific) and PGE2 (#514010, Cayman Chemicals, Ann Arbor, MI, USA) according to the manufacturer's instructions
.png)
